YiChang HEC ChangJiang Pharmaceutical Co Ltd
HKEX:1558
Income Statement
Earnings Waterfall
YiChang HEC ChangJiang Pharmaceutical Co Ltd
Revenue
|
6.3B
CNY
|
Cost of Revenue
|
-1.3B
CNY
|
Gross Profit
|
5B
CNY
|
Operating Expenses
|
-2.1B
CNY
|
Operating Income
|
2.9B
CNY
|
Other Expenses
|
-905.4m
CNY
|
Net Income
|
2B
CNY
|
Income Statement
YiChang HEC ChangJiang Pharmaceutical Co Ltd
Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
693
N/A
|
866
+25%
|
942
+9%
|
1 048
+11%
|
1 602
+53%
|
2 422
+51%
|
2 510
+4%
|
4 099
+63%
|
6 224
+52%
|
5 236
-16%
|
2 348
-55%
|
467
-80%
|
914
+96%
|
2 005
+119%
|
3 745
+87%
|
5 661
+51%
|
6 295
+11%
|
|
Gross Profit | ||||||||||||||||||
Cost of Revenue |
(178)
|
(216)
|
(214)
|
(200)
|
(280)
|
(398)
|
(399)
|
(610)
|
(922)
|
(824)
|
(352)
|
(101)
|
(430)
|
(661)
|
(899)
|
(1 211)
|
(1 309)
|
|
Gross Profit |
515
N/A
|
650
+26%
|
727
+12%
|
849
+17%
|
1 321
+56%
|
2 024
+53%
|
2 112
+4%
|
3 489
+65%
|
5 302
+52%
|
4 412
-17%
|
1 997
-55%
|
101
-95%
|
484
+380%
|
1 344
+178%
|
2 846
+112%
|
4 449
+56%
|
4 986
+12%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(185)
|
(240)
|
(308)
|
(296)
|
(558)
|
(885)
|
(1 023)
|
(1 876)
|
(2 865)
|
(2 356)
|
(1 294)
|
(904)
|
(928)
|
(1 135)
|
(1 664)
|
(1 970)
|
(2 088)
|
|
Selling, General & Administrative |
(197)
|
(274)
|
(314)
|
(322)
|
(565)
|
(897)
|
(1 038)
|
(1 843)
|
(2 869)
|
(2 454)
|
(1 560)
|
(1 126)
|
(883)
|
(1 097)
|
(1 551)
|
(1 801)
|
(1 939)
|
|
Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(50)
|
(110)
|
(101)
|
(130)
|
(187)
|
(192)
|
|
Other Operating Expenses |
12
|
35
|
6
|
25
|
7
|
12
|
16
|
(33)
|
5
|
98
|
266
|
272
|
65
|
63
|
17
|
18
|
44
|
|
Operating Income |
329
N/A
|
411
+25%
|
420
+2%
|
552
+32%
|
763
+38%
|
1 139
+49%
|
1 089
-4%
|
1 613
+48%
|
2 438
+51%
|
2 057
-16%
|
702
-66%
|
(539)
N/A
|
(444)
+18%
|
209
N/A
|
1 182
+466%
|
2 480
+110%
|
2 898
+17%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
(15)
|
(15)
|
34
|
(5)
|
(14)
|
(3)
|
13
|
(85)
|
(168)
|
(199)
|
313
|
210
|
(178)
|
(265)
|
(853)
|
(807)
|
(285)
|
|
Non-Reccuring Items |
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
(3)
|
(5)
|
(7)
|
(45)
|
(60)
|
(290)
|
(335)
|
(486)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
315
N/A
|
396
+26%
|
453
+14%
|
547
+21%
|
748
+37%
|
1 137
+52%
|
1 102
-3%
|
1 528
+39%
|
2 269
+48%
|
1 854
-18%
|
1 010
-46%
|
(336)
N/A
|
(667)
-99%
|
(115)
+83%
|
39
N/A
|
1 338
+3 293%
|
2 127
+59%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
(49)
|
(69)
|
(72)
|
(86)
|
(122)
|
(195)
|
(201)
|
(277)
|
(362)
|
(290)
|
(173)
|
49
|
79
|
2
|
10
|
(232)
|
(271)
|
|
Income from Continuing Operations |
266
|
328
|
381
|
461
|
626
|
942
|
901
|
1 251
|
1 907
|
1 564
|
837
|
(286)
|
(588)
|
(113)
|
49
|
1 106
|
1 856
|
|
Income to Minority Interest |
0
|
0
|
0
|
7
|
21
|
38
|
41
|
26
|
12
|
4
|
2
|
1
|
0
|
(0)
|
27
|
33
|
137
|
|
Net Income (Common) |
266
N/A
|
328
+23%
|
381
+16%
|
467
+23%
|
647
+38%
|
980
+51%
|
943
-4%
|
1 276
+35%
|
1 919
+50%
|
1 568
-18%
|
839
-46%
|
(285)
N/A
|
(588)
-106%
|
(113)
+81%
|
77
N/A
|
1 139
+1 387%
|
1 993
+75%
|
|
EPS (Diluted) |
0.4
N/A
|
0.72
+80%
|
0.42
-42%
|
1.04
+148%
|
0.72
-31%
|
1.08
+50%
|
1.04
-4%
|
1.41
+36%
|
1.88
+33%
|
1.41
-25%
|
0.75
-47%
|
-0.32
N/A
|
-0.67
-109%
|
-0.13
+81%
|
0.09
N/A
|
1.29
+1 333%
|
2.26
+75%
|